[go: up one dir, main page]

FI970058A0 - Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa - Google Patents

Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa

Info

Publication number
FI970058A0
FI970058A0 FI970058A FI970058A FI970058A0 FI 970058 A0 FI970058 A0 FI 970058A0 FI 970058 A FI970058 A FI 970058A FI 970058 A FI970058 A FI 970058A FI 970058 A0 FI970058 A0 FI 970058A0
Authority
FI
Finland
Prior art keywords
omeprazole
pharmaceutical formulation
formulation containing
magnesium salt
oral pharmaceutical
Prior art date
Application number
FI970058A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI970058L (fi
FI970058A7 (fi
Inventor
Siv Inga Bengtsson
Kurt Ingmar Loevgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of FI970058A0 publication Critical patent/FI970058A0/fi
Publication of FI970058L publication Critical patent/FI970058L/fi
Publication of FI970058A7 publication Critical patent/FI970058A7/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI970058A 1994-07-08 1995-07-03 Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omep ratsolin magnesiumsuolaa FI970058A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9400679 1994-07-08
PCT/SE1995/000816 WO1996001622A1 (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole

Publications (3)

Publication Number Publication Date
FI970058A0 true FI970058A0 (fi) 1997-01-07
FI970058L FI970058L (fi) 1997-01-07
FI970058A7 FI970058A7 (fi) 1997-01-07

Family

ID=20393105

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970058A FI970058A7 (fi) 1994-07-08 1995-07-03 Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omep ratsolin magnesiumsuolaa

Country Status (15)

Country Link
EP (1) EP0768872A1 (sk)
KR (1) KR970704426A (sk)
BR (1) BR9508261A (sk)
CA (1) CA2193681A1 (sk)
CZ (1) CZ379596A3 (sk)
EE (1) EE03378B1 (sk)
FI (1) FI970058A7 (sk)
HU (1) HUT78132A (sk)
IS (1) IS4398A (sk)
MX (1) MX9700152A (sk)
NO (1) NO970036L (sk)
NZ (1) NZ289958A (sk)
PL (1) PL181265B1 (sk)
SK (1) SK281803B6 (sk)
WO (1) WO1996001622A1 (sk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5900258A (en) * 1996-02-01 1999-05-04 Zeolitics Inc. Anti-bacterial compositions
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
CA2413923A1 (en) * 2000-03-09 2001-09-13 Andrew Ilchyshyn Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2008502740A (ja) * 2004-06-15 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド ベンズイミダゾール化合物の安定医薬製剤
CN105106168B (zh) * 2015-08-19 2018-03-06 德州德药制药有限公司 一种埃索美拉唑镁肠胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
WO1996001622A1 (en) 1996-01-25
HUT78132A (hu) 2000-06-28
SK281803B6 (sk) 2001-08-06
PL318464A1 (en) 1997-06-09
MX9700152A (es) 1997-04-30
NO970036D0 (no) 1997-01-06
SK166096A3 (en) 1997-09-10
WO1996001622A8 (en) 1999-12-23
CA2193681A1 (en) 1996-01-25
EE9700014A (et) 1997-06-16
HU9700039D0 (en) 1997-02-28
IS4398A (is) 1996-12-17
KR970704426A (ko) 1997-09-06
EE03378B1 (et) 2001-04-16
EP0768872A1 (en) 1997-04-23
FI970058L (fi) 1997-01-07
PL181265B1 (pl) 2001-06-29
NO970036L (no) 1997-01-06
AU695723B2 (en) 1998-08-20
FI970058A7 (fi) 1997-01-07
BR9508261A (pt) 1997-12-23
NZ289958A (en) 1998-09-24
AU2994795A (en) 1996-02-09
CZ379596A3 (en) 1997-08-13

Similar Documents

Publication Publication Date Title
FI970058A0 (fi) Uusi suun kautta annettava farmaseuttinen valmiste, joka sisältää omepratsolin magnesiumsuolaa
NO995809D0 (no) Farmasöytisk formulering av omeprazol
NO994757D0 (no) FramgangsmÕte for oral administrasjon av proteiner
DK0754061T3 (da) Ny oral farmaceutisk doseringsform
ATE206924T1 (de) Oral anzuwendende arzneizubereitung enthaltend olanzapin
NO934547D0 (no) Oral behandling av Helicobacter-in-feksjon
ATE178489T1 (de) Fluessige oral anzuwendende arzneizubereitungen enthaltend paroxetinresinate
NO20001962D0 (no) Terapeutisk anvendelse av kinolinderivater
DK0936913T4 (da) Oralt farmaceutisk præparat indeholdende ibandronat
DE59910858D1 (de) Pharmazeutische zubereitung von moxifloxacin
ATE260659T1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
FI955310L (fi) Farmaseuttinen koostumus flavonoidien antamiseksi oraalisesti
NO308580B1 (no) Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin
EE04015B1 (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nendevalmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
NO953367L (no) Anvendelse av substituerte 4-fenyl-6-amino-nikotinsyre-derivater som legemidler
DE59711379D1 (de) Oral applizierbare formulierungen von chinolon- oder naphthyridoncarbonsäuren
ITMI921123A0 (it) Formulazioni farmaceutiche orali contenenti antocianosidi
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
ITMI932014A0 (it) Composizioni farmaceutiche orali effervescenti contenenti estrone
NO975680L (no) Oralt, farmasöytisk preparat av piperidinoalkanol-forbindelser i opplösningsform
DE69832974D1 (de) Gerät zur intrakardialen verabreichung von medikamenten
HK1008297A (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole
NO993928D0 (no) Farmasöytisk blanding for oral administrasjon av heterosykliske forbindelser i form av kvaternær ammonium
NO930017D0 (no) Innretning for oral administrering av vaeske